Full Text of SB3502 98th General Assembly
SB3502 98TH GENERAL ASSEMBLY |
| | 98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014 SB3502 Introduced 2/14/2014, by Sen. David Koehler SYNOPSIS AS INTRODUCED: |
| 720 ILCS 570/208 | from Ch. 56 1/2, par. 1208 |
|
Amends the Illinois Controlled Substances Act. Provides that substances containing ephedrine or pseudoephedrine, their salts or optical isomers, or salts of optical isomers, are Schedule III controlled substances and require a prescription.
|
| |
| | A BILL FOR |
|
| | | SB3502 | | LRB098 19436 JLK 54598 b |
|
| 1 | | AN ACT concerning criminal law.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 208 as follows:
| 6 | | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)
| 7 | | Sec. 208.
(a) The controlled substances listed in this | 8 | | Section are
included in Schedule III.
| 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another
schedule, any material, compound, mixture, or | 11 | | preparation which contains
any quantity of the following | 12 | | substances having a stimulant effect on
the central nervous | 13 | | system, including its salts, isomers (whether
optical | 14 | | position, or geometric), and salts of such isomers whenever the
| 15 | | existence of such salts, isomers, and salts of isomers is | 16 | | possible
within the specific chemical designation;
| 17 | | (1) Those compounds, mixtures, or preparations in | 18 | | dosage unit form
containing any stimulant substances | 19 | | listed in Schedule II which
compounds, mixtures, or | 20 | | preparations were listed on August 25, 1971, as
excepted | 21 | | compounds under Title 21, Code of Federal Regulations, | 22 | | Section
308.32, and any other drug of the quantitative | 23 | | composition shown in that
list for those drugs or which is |
| | | SB3502 | - 2 - | LRB098 19436 JLK 54598 b |
|
| 1 | | the same except that it contains a
lesser quantity of | 2 | | controlled substances;
| 3 | | (2) Benzphetamine;
| 4 | | (3) Chlorphentermine;
| 5 | | (4) Clortermine;
| 6 | | (5) Phendimetrazine.
| 7 | | (c) Unless specifically excepted or unless listed in | 8 | | another
schedule, any material, compound, mixture, or | 9 | | preparation which contains
any quantity of the following | 10 | | substances having a potential for abuse
associated with a | 11 | | depressant effect on the central nervous system:
| 12 | | (1) Any compound, mixture, or preparation containing | 13 | | amobarbital,
secobarbital, pentobarbital or any salt | 14 | | thereof and one or more other
active medicinal ingredients | 15 | | which are not listed in any schedule;
| 16 | | (2) Any suppository dosage form containing | 17 | | amobarbital,
secobarbital, pentobarbital or any salt of | 18 | | any of these drugs and
approved by the Federal Food and | 19 | | Drug Administration for marketing only
as a suppository;
| 20 | | (3) Any substance which contains any quantity of a | 21 | | derivative of
barbituric acid, or any salt thereof:
| 22 | | (3.1) Aprobarbital; | 23 | | (3.2) Butabarbital (secbutabarbital); | 24 | | (3.3) Butalbital; | 25 | | (3.4) Butobarbital (butethal);
| 26 | | (4) Chlorhexadol;
|
| | | SB3502 | - 3 - | LRB098 19436 JLK 54598 b |
|
| 1 | | (5) Methyprylon;
| 2 | | (6) Sulfondiethylmethane;
| 3 | | (7) Sulfonethylmethane;
| 4 | | (8) Sulfonmethane;
| 5 | | (9) Lysergic acid;
| 6 | | (10) Lysergic acid amide;
| 7 | | (10.1) Tiletamine or zolazepam or both, or any salt of | 8 | | either of them.
| 9 | | Some trade or other names for a tiletamine-zolazepam
| 10 | | combination product: Telazol.
| 11 | | Some trade or other names for Tiletamine:
| 12 | | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| 13 | | Some trade or other names for zolazepam:
| 14 | | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| 15 | | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
| 16 | | (11) Any material, compound, mixture or preparation | 17 | | containing not more
than 12.5 milligrams of pentazocine or | 18 | | any of its salts, per 325 milligrams of
aspirin;
| 19 | | (12) Any material, compound, mixture or preparation | 20 | | containing not
more than 12.5 milligrams of pentazocine or | 21 | | any of its salts, per 325
milligrams of acetaminophen;
| 22 | | (13) Any material, compound, mixture or preparation | 23 | | containing not more
than 50 milligrams of pentazocine or | 24 | | any of its salts plus naloxone HCl USP
0.5 milligrams, per | 25 | | dosage unit;
| 26 | | (14) Ketamine;
|
| | | SB3502 | - 4 - | LRB098 19436 JLK 54598 b |
|
| 1 | | (15) Thiopental. | 2 | | (d) Nalorphine.
| 3 | | (d.5) Buprenorphine. | 4 | | (e) Unless specifically excepted or unless listed in | 5 | | another
schedule, any material, compound, mixture, or | 6 | | preparation containing
limited quantities of any of the | 7 | | following narcotic drugs, or their salts
calculated as the free | 8 | | anhydrous base or alkaloid, as set forth below:
| 9 | | (1) not more than 1.8 grams of codeine per 100
| 10 | | milliliters or not more than 90 milligrams per dosage unit, | 11 | | with an
equal or greater quantity of an isoquinoline | 12 | | alkaloid of opium;
| 13 | | (2) not more than 1.8 grams of codeine per 100
| 14 | | milliliters or not more than 90 milligrams per dosage unit, | 15 | | with one or
more active non-narcotic ingredients in | 16 | | recognized therapeutic amounts;
| 17 | | (3) not more than 300 milligrams of dihydrocodeinone | 18 | | per 100 milliliters
or not more than 15 milligrams per | 19 | | dosage
unit, with a fourfold or greater quantity of an | 20 | | isoquinoline alkaloid of
opium;
| 21 | | (4) not more than 300 milligrams of dihydrocodeinone | 22 | | per 100 milliliters
or not more than 15 milligrams per | 23 | | dosage
unit, with one or more active, non-narcotic | 24 | | ingredients in recognized
therapeutic amounts;
| 25 | | (5) not more than 1.8 grams of dihydrocodeine
per 100 | 26 | | milliliters or not more than 90 milligrams per dosage unit, |
| | | SB3502 | - 5 - | LRB098 19436 JLK 54598 b |
|
| 1 | | with
one or more active, non-narcotic ingredients in | 2 | | recognized therapeutic
amounts;
| 3 | | (6) not more than 300 milligrams of ethylmorphine per | 4 | | 100 milliliters
or not more than 15 milligrams per dosage
| 5 | | unit, with one or more active, non-narcotic ingredients in | 6 | | recognized
therapeutic amounts;
| 7 | | (7) not more than 500 milligrams of opium per 100 | 8 | | milliliters or per
100 grams, or not more than 25 | 9 | | milligrams per dosage unit, with one or
more active, | 10 | | non-narcotic ingredients in recognized therapeutic | 11 | | amounts;
| 12 | | (8) not more than 50 milligrams of morphine
per 100 | 13 | | milliliters or per 100 grams with one or more active,
| 14 | | non-narcotic ingredients in recognized therapeutic | 15 | | amounts.
| 16 | | (f) Anabolic steroids, except the following anabolic | 17 | | steroids that are
exempt:
| 18 | | (1) Androgyn L.A.;
| 19 | | (2) Andro-Estro 90-4;
| 20 | | (3) depANDROGYN;
| 21 | | (4) DEPO-T.E.;
| 22 | | (5) depTESTROGEN;
| 23 | | (6) Duomone;
| 24 | | (7) DURATESTRIN;
| 25 | | (8) DUO-SPAN II;
| 26 | | (9) Estratest;
|
| | | SB3502 | - 6 - | LRB098 19436 JLK 54598 b |
|
| 1 | | (10) Estratest H.S.;
| 2 | | (11) PAN ESTRA TEST;
| 3 | | (12) Premarin with Methyltestosterone;
| 4 | | (13) TEST-ESTRO Cypionates;
| 5 | | (14) Testosterone Cyp 50 Estradiol Cyp 2;
| 6 | | (15) Testosterone Cypionate-Estradiol Cypionate | 7 | | injection; and
| 8 | | (16) Testosterone Enanthate-Estradiol Valerate | 9 | | injection.
| 10 | | (g) Hallucinogenic
substances.
| 11 | | (1) Dronabinol (synthetic) in sesame oil and | 12 | | encapsulated in a soft
gelatin capsule in a U.S.
Food and | 13 | | Drug Administration approved product. Some other names for
| 14 | | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
| 15 | | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)
pyran-1-ol) or | 16 | | (-)-delta-9-(trans)-tetrahydrocannabinol.
| 17 | | (2) (Reserved).
| 18 | | (g-5) Ephedrine or pseudoephedrine, their salts or optical | 19 | | isomers, or salts of optical isomers. | 20 | | (h) The Department may except by rule any compound, | 21 | | mixture, or
preparation containing any stimulant or depressant | 22 | | substance listed in
subsection (b) from the application of all | 23 | | or any part of this
Act if the compound, mixture, or | 24 | | preparation contains one or more active
medicinal ingredients | 25 | | not having a stimulant or depressant effect on the
central | 26 | | nervous system, and if the admixtures are included therein in
|
| | | SB3502 | - 7 - | LRB098 19436 JLK 54598 b |
|
| 1 | | combinations, quantity, proportion, or concentration that | 2 | | vitiate the
potential for abuse of the substances which have a | 3 | | stimulant or
depressant effect on the central nervous system.
| 4 | | (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10; | 5 | | 97-334, eff. 1-1-12.)
|
|